HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency
July 15, 2021 20:00 ET
|
HUTCHMED (China) Limited
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in...
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
July 13, 2021 02:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China...
HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering
July 12, 2021 09:52 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX:13) today announces the full exercise...
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
July 05, 2021 19:00 ET
|
HUTCHMED (China) Limited
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., July 05, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) has initiated a Phase I study of HMPL-295, its...
HUTCHMED to Announce 2021 Half-Year Financial Results
July 02, 2021 04:30 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and & FLORHAM PARK, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results...
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
July 01, 2021 06:00 ET
|
HUTCHMED (China) Limited
– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China – HONG KONG and SHANGHAI,...
HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong
June 30, 2021 05:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the listing of its...
HUTCHMED Announces Pricing of Global Offering
June 23, 2021 10:22 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the pricing of its...
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
June 22, 2021 13:16 ET
|
HUTCHMED (China) Limited
– First selective MET inhibitor approval in China in this setting – – First regulatory approval for the oral, potent and selective MET tyrosine kinase inhibitor – HONG KONG and SHANGHAI, China...
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors
June 18, 2021 11:24 ET
|
HUTCHMED (China) Limited
– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with...